DK2306977T3 - Fremgangsmåde og sammensætning til behandling af okulær hypertension og glaukom - Google Patents

Fremgangsmåde og sammensætning til behandling af okulær hypertension og glaukom

Info

Publication number
DK2306977T3
DK2306977T3 DK09754864.8T DK09754864T DK2306977T3 DK 2306977 T3 DK2306977 T3 DK 2306977T3 DK 09754864 T DK09754864 T DK 09754864T DK 2306977 T3 DK2306977 T3 DK 2306977T3
Authority
DK
Denmark
Prior art keywords
glaucoma
treatment
composition
ocular hypertension
ocular
Prior art date
Application number
DK09754864.8T
Other languages
Danish (da)
English (en)
Inventor
Timo Reunamaki
Pertti Pellinen
Olli Oksala
Kari Lehmussaari
Original Assignee
Santen Pharmaceutical Co Ltd
Asahi Glass Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39940592&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2306977(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Santen Pharmaceutical Co Ltd, Asahi Glass Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Application granted granted Critical
Publication of DK2306977T3 publication Critical patent/DK2306977T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK09754864.8T 2008-05-30 2009-05-28 Fremgangsmåde og sammensætning til behandling af okulær hypertension og glaukom DK2306977T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08397513A EP2127638A1 (en) 2008-05-30 2008-05-30 Method and composition for treating ocular hypertension and glaucoma
PCT/JP2009/060211 WO2009145356A1 (en) 2008-05-30 2009-05-28 Method and composition for treating ocular hypertension and glaucoma

Publications (1)

Publication Number Publication Date
DK2306977T3 true DK2306977T3 (da) 2014-09-15

Family

ID=39940592

Family Applications (4)

Application Number Title Priority Date Filing Date
DK09754864.8T DK2306977T3 (da) 2008-05-30 2009-05-28 Fremgangsmåde og sammensætning til behandling af okulær hypertension og glaukom
DK17000440.2T DK3205334T3 (da) 2008-05-30 2009-05-28 Fremgangsmåde og sammensætning til behandling okulær hypertension og glaukom
DK14001862.3T DK2772249T3 (en) 2008-05-30 2009-05-28 Method and composition for the treatment of ocular hypertension and glaucoma
DK20164602.3T DK3714877T3 (da) 2008-05-30 2009-05-28 Fremgangsmåde og sammensætning til behandling af okulær hypertension og glaukom

Family Applications After (3)

Application Number Title Priority Date Filing Date
DK17000440.2T DK3205334T3 (da) 2008-05-30 2009-05-28 Fremgangsmåde og sammensætning til behandling okulær hypertension og glaukom
DK14001862.3T DK2772249T3 (en) 2008-05-30 2009-05-28 Method and composition for the treatment of ocular hypertension and glaucoma
DK20164602.3T DK3714877T3 (da) 2008-05-30 2009-05-28 Fremgangsmåde og sammensætning til behandling af okulær hypertension og glaukom

Country Status (27)

Country Link
US (3) US9999593B2 (enExample)
EP (8) EP2127638A1 (enExample)
JP (9) JP2011521943A (enExample)
KR (5) KR101988642B1 (enExample)
CN (1) CN102083413B (enExample)
AR (2) AR071937A1 (enExample)
AU (1) AU2009252210C1 (enExample)
BR (1) BRPI0913109B8 (enExample)
CA (2) CA2965185A1 (enExample)
CY (2) CY1115565T1 (enExample)
DK (4) DK2306977T3 (enExample)
EA (1) EA023661B1 (enExample)
ES (6) ES2968837T3 (enExample)
GE (1) GEP20156220B (enExample)
HR (4) HRP20220361T1 (enExample)
HU (3) HUE058079T2 (enExample)
JO (1) JO3039B1 (enExample)
LT (3) LT2772249T (enExample)
MX (1) MX2010012987A (enExample)
MY (1) MY159463A (enExample)
PL (4) PL3714877T3 (enExample)
PT (4) PT3205334T (enExample)
SG (1) SG191628A1 (enExample)
SI (4) SI2772249T1 (enExample)
TW (1) TWI432202B (enExample)
UA (1) UA102257C2 (enExample)
WO (1) WO2009145356A1 (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
EP2228058A1 (en) 2009-03-04 2010-09-15 Novagali Pharma S.A. Anionic oil-in-water emulsion containing prostaglandins and uses thereof
EP2389939A1 (en) 2010-05-28 2011-11-30 Novagali Pharma S.A. Use of prostaglandins F2alpha and analogues for the healing of corneal and conjunctival lesions
US20110136872A1 (en) * 2009-12-09 2011-06-09 Burk Robert M Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
JP5681472B2 (ja) * 2009-12-28 2015-03-11 ロート製薬株式会社 眼科用組成物
FR2961694B1 (fr) * 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
US10154923B2 (en) * 2010-07-15 2018-12-18 Eyenovia, Inc. Drop generating device
EP2598118B1 (en) * 2010-07-29 2018-09-05 Allergan, Inc. Preservative free bimatoprost and timolol solutions
WO2012015996A2 (en) * 2010-07-29 2012-02-02 Allergan, Inc. Preservative free bimatoprost solutions
US9061034B2 (en) 2010-07-29 2015-06-23 Allergan, Inc. Preservative free bimatoprost and timolol solutions
WO2012021107A2 (en) 2010-08-12 2012-02-16 Nanyang Technological University A liposomal formulation for ocular drug delivery
EP2618810B1 (en) 2010-09-21 2016-11-23 S & V Technologies GmbH Cosmetic composition
EP2452669A1 (en) * 2010-10-29 2012-05-16 Omnivision GmbH Ophthalmic composition
US20120263803A1 (en) * 2011-04-12 2012-10-18 R-Tech Ueno, Ltd. Aqueous ophthalmic composition
CN102716074B (zh) * 2012-06-28 2013-10-16 武汉武药科技有限公司 一种贝美前列素滴眼剂及其制备方法
EP2887923B1 (en) 2012-08-24 2023-04-05 Sun Pharmaceutical Industries Limited Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions
US9956195B2 (en) 2014-01-07 2018-05-01 Nanyang Technological University Stable liposomal formulations for ocular drug delivery
EP3091985B1 (en) 2014-01-10 2024-05-08 Manistee Therapeutics, Inc. Prostanglandins for topical use in the treatment of migraines.
CN104766952B (zh) * 2015-04-21 2017-01-25 武汉凯迪工程技术研究总院有限公司 利用生物质气化炉滤渣制备锂离子电池负极材料的方法
PL3103439T3 (pl) 2015-06-09 2019-12-31 Medproject Pharma-Entwicklungs- Und Vertriebsgesellschaft Mbh Zdolny do tworzenia kropli oftalmiczny żel bimatoprostu
US10105371B2 (en) * 2015-10-09 2018-10-23 Tamara Vrabec Use of medications with neuroprotective properties to prevent or reduce the risk of ischemia-reperfusion injury in a subject
US20180325854A1 (en) * 2015-11-06 2018-11-15 Accuitis Pharmaceuticals, Inc. Use of proteasome inhibitors to treat ocular disorders
US20190231885A1 (en) 2015-11-10 2019-08-01 Sun Pharma Global Fze Topical formulations and uses thereof
SG11201906729RA (en) 2016-02-29 2019-08-27 Sun Pharma Global Fze Topical cyclosporine-containing formulations and uses thereof
GR1009040B (el) * 2016-04-19 2017-05-19 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο οφθαλμικο σκευασμα ελευθερο συντηρητικου
WO2018033854A1 (en) * 2016-08-15 2018-02-22 Santen Pharmaceutical Co., Ltd. Ophthalmic composition and a method for treating ocular hypertension and glaucoma
KR101770324B1 (ko) * 2016-11-09 2017-08-22 주식회사태준제약 안압 강하용 점안 조성물
JP2020059652A (ja) * 2016-12-26 2020-04-16 参天製薬株式会社 タフルプロストとクエン酸エステルとを含有するデポ剤
EP4285908A3 (en) * 2017-03-27 2024-02-14 Alcon Inc. Pharmaceutical preparation
US20180318319A1 (en) * 2017-05-04 2018-11-08 Ocular Science, Inc. Compositions and Methods for Treating Eyes and Methods of Preparation
EP3643297A4 (en) 2017-06-22 2021-03-17 Yonsung Fine Chemical Co., Ltd. OPHTHALMIC COMPOSITION FOR THE TREATMENT OF GLAUCOMA
ES2972934T3 (es) * 2017-12-21 2024-06-17 Santen Pharmaceutical Co Ltd Combinación de sepetaprost y ripasudil para su uso en la profilaxis o tratamiento del glaucoma o hipertensión ocular
WO2020013717A1 (en) 2018-07-09 2020-01-16 Warszawskie Zaklady Farmaceutyczne Polfa Sa Ophthalmic dispensing device
JP7599838B2 (ja) * 2019-04-10 2024-12-16 参天製薬株式会社 エピナスチン又はその塩を含有する水性医薬組成物
CN111632025A (zh) * 2020-03-04 2020-09-08 吉林大学第一医院 一种贝美前列素眼用温度敏感型原位凝胶及其制备方法与应用
CN111840225B (zh) * 2020-08-12 2021-09-14 陈丽娜 一种用于治疗青光眼的滴眼剂及其制备方法
RU2761625C2 (ru) * 2021-02-11 2021-12-13 Общество с ограниченной ответственностью "Гротекс" (ООО "Гротекс") Фармацевтическая композиция тафлупроста
CN116687842A (zh) * 2022-02-28 2023-09-05 山东新时代药业有限公司 一种拉坦前列素滴眼液及其制备方法
US20250213510A1 (en) * 2022-03-25 2025-07-03 Tsubota Laboratory, Inc. Aqueous Composition
WO2023241652A1 (zh) * 2022-06-16 2023-12-21 广州润尔眼科生物科技有限公司 一种药物组合物及其制备方法和应用
TW202444342A (zh) * 2023-03-24 2024-11-16 日商坪田實驗室股份有限公司 水性組成物
CN121057582A (zh) * 2023-05-11 2025-12-02 特一华制药株式会社 抑制了前列腺素F2α衍生物的含有率降低的产品
JP7757564B1 (ja) * 2024-06-28 2025-10-21 東亜薬品株式会社 水性組成物

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4778815A (en) * 1987-03-18 1988-10-18 Ciba-Geigy Corporation Method of inhibiting cataracts by topical application of a 2-substituted 1,2-benzisoselenazol-3(2H)-one
ES2042625T5 (es) 1987-04-03 2000-07-16 Univ Columbia Uso de una prostaglandina en combinacion con un agente bloqueante adrenergico para la reduccion de presion intraocular.
US5409125A (en) 1989-12-11 1995-04-25 Aktiebolaget Astra Unit dose container
DE4027320C2 (de) 1990-08-29 1993-09-30 Ursapharm Arzneimittel Gmbh Fluid-Abgabeeinrichtung für keimfreies Fluid
JPH0655640A (ja) 1992-08-04 1994-03-01 Aavan Internatl:Kk 洗面台カウンター及びその製造方法
JPH06107547A (ja) 1992-10-01 1994-04-19 Aarutetsuku Ueno:Kk 眼科用組成物
AU665287B2 (en) 1992-12-21 1995-12-21 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
JP2510066Y2 (ja) 1993-01-20 1996-09-11 東洋製罐株式会社 加熱殺菌可能な液体医薬容器
US5807892A (en) 1994-09-30 1998-09-15 Alcon Laboratories, Inc. Use of certain prostaglandin analogues to treat glaucoma and ocular hypertension
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
AU704938B2 (en) * 1995-11-17 1999-05-06 Alcon Laboratories, Inc. Combination therapy for treating glaucoma
ATE221048T1 (de) 1996-09-17 2002-08-15 Asahi Glass Co Ltd Fluorierte prostaglandinderivate und medikamente
US6241124B1 (en) 1996-12-09 2001-06-05 Bausch & Lomb Incorporated Single-use container
JP3480549B2 (ja) 1996-12-26 2003-12-22 参天製薬株式会社 ジフルオロプロスタグランジン誘導体およびその用途
AR002194A1 (es) 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
ES2265166T3 (es) 1997-10-13 2007-02-01 R-Tech Ueno, Ltd. Composicion para tratamiento de hipertension intraocular o glaucoma.
US6066671A (en) 1997-12-19 2000-05-23 Alcon Laboratories, Inc. Treatment of GLC1A glaucoma with 3-benzoyl-phenylacetic acids, esters, or amides
GB2337740B (en) 1998-05-26 2000-11-15 Spreckelsen Mcgeough Ltd Fluid packaging
US6235781B1 (en) 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
WO2000003736A1 (en) * 1998-07-14 2000-01-27 Alcon Laboratories, Inc. Prostaglandin product
AU761785B2 (en) 1998-09-25 2003-06-12 Alcon Laboratories, Inc. Sustained release, and comfortable ophthalmic composition and method for ocular therapy
US6096783A (en) 1998-12-15 2000-08-01 Alcon Laboratories, Inc. Cyclobutane prostaglandin analogues as ocular hypotensive agents
WO2000038663A2 (en) 1998-12-24 2000-07-06 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
CZ20013607A3 (cs) 1999-04-06 2002-06-12 Sepracor Inc. Farmaceutický prostředek
EP1312380B1 (en) 2000-06-19 2006-05-03 Santen Pharmaceutical Co., Ltd. Aseptics
EP1321144B1 (en) 2000-09-13 2010-12-08 Santen Pharmaceutical Co., Ltd. Eye drops
JP3876355B2 (ja) 2000-09-13 2007-01-31 参天製薬株式会社 点眼液
TW586946B (en) 2000-12-22 2004-05-11 Novartis Ag Process to improve stability
WO2004006826A1 (ja) 2002-07-16 2004-01-22 Senju Pharmaceutical Co., Ltd. 薬液容器及びその製造方法
CA2707067C (en) 2002-09-09 2013-07-16 Santen Pharmaceutical Co., Ltd. Clear ophthalmic solution comprising latanoprost as active ingredient
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
US20060199863A1 (en) 2003-07-31 2006-09-07 Santen Pharmaceutical Co., Ltd. Product containing prostaglandin
US20050287325A1 (en) 2004-06-25 2005-12-29 Pharmacia & Upjohn Company Pharmaceutical containers with low adsorption/absorption of active ingredients, and a method of testing materials for adsorption/absorption of active ingredients
ATE412400T1 (de) 2004-11-09 2008-11-15 Novagali Pharma Sa Öl-in-wasser-emulsion mit niedriger konzentration des kationischen mittels und positivem zetapotential
WO2006058139A2 (en) 2004-11-24 2006-06-01 Holopack International Corp. Dispensing container with flow control system
CN101072568A (zh) 2004-12-09 2007-11-14 参天制药株式会社 含有分子内具有氟原子的前列腺素的制品
ES2386148T3 (es) 2004-12-24 2012-08-10 Santen Pharmaceutical Co., Ltd. Productos que contienen un derivado de prostaglandina F2 alfa
GB0501192D0 (en) * 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
KR101354892B1 (ko) 2005-07-13 2014-01-22 산텐 세이야꾸 가부시키가이샤 안과용 방부 조성물
ES2460967T3 (es) 2005-08-02 2014-05-16 Santen Pharmaceutical Co., Ltd. Método para la prevención de la degradación de una sustancia térmicamente inestable
DE602006016628D1 (de) 2005-10-10 2010-10-14 Novagali Pharma Sa Prostaglandine enthaltende ophthalmische emulsionen
FI126233B (sv) 2006-02-23 2016-08-31 Oy Kwh Mirka Ab Oscillerande slipmaskin
FR2918891B1 (fr) 2007-07-20 2009-09-25 Thea Sa Lab Solution ophtalmique a base de prostaglandines sans conservateur
KR100927617B1 (ko) 2007-11-26 2009-11-23 한국표준과학연구원 열분해 탄소 성분의 나노 크기를 가지는 바이오 센서의감지부를 제작하는 방법
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma

Also Published As

Publication number Publication date
KR20160102319A (ko) 2016-08-29
AU2009252210B2 (en) 2014-10-16
CN102083413A (zh) 2011-06-01
CN102083413B (zh) 2013-11-06
ES2968837T3 (es) 2024-05-14
EP4289446A3 (en) 2024-01-10
HRP20170769T1 (hr) 2017-08-11
KR101988642B1 (ko) 2019-06-12
EP3714877A1 (en) 2020-09-30
JP6649992B2 (ja) 2020-02-19
KR102114401B1 (ko) 2020-05-25
JP2014133765A (ja) 2014-07-24
PL2772249T3 (pl) 2017-10-31
EP2127638A1 (en) 2009-12-02
EP2306977B1 (en) 2014-08-13
US10864159B2 (en) 2020-12-15
DK3205334T3 (da) 2020-07-13
EP2772249B1 (en) 2017-05-03
JP6148317B2 (ja) 2017-06-14
HRP20200998T1 (hr) 2020-10-16
TW201000104A (en) 2010-01-01
PT3714877T (pt) 2022-03-10
SG191628A1 (en) 2013-07-31
JP2020073574A (ja) 2020-05-14
BRPI0913109B1 (pt) 2019-10-22
KR102246598B1 (ko) 2021-04-30
AU2009252210C1 (en) 2016-04-14
EA023661B1 (ru) 2016-06-30
CA2965185A1 (en) 2009-12-03
EP3205334A1 (en) 2017-08-16
HUE049923T2 (hu) 2020-11-30
HUE058079T2 (hu) 2022-06-28
BRPI0913109B8 (pt) 2021-05-25
LT3205334T (lt) 2020-09-25
HRP20220361T1 (hr) 2022-05-13
JP7520285B2 (ja) 2024-07-23
LT3714877T (lt) 2022-04-11
ES2808050T3 (es) 2021-02-25
UA102257C2 (uk) 2013-06-25
WO2009145356A1 (en) 2009-12-03
KR20180008905A (ko) 2018-01-24
JP2023085558A (ja) 2023-06-20
EP4512424A3 (en) 2025-03-05
CA2724194C (en) 2017-06-27
JP6356868B2 (ja) 2018-07-11
AR120961A2 (es) 2022-04-06
SI2306977T1 (sl) 2014-12-31
SI3205334T1 (sl) 2020-10-30
LT2772249T (lt) 2017-09-11
PT2772249T (pt) 2017-08-08
ES2627837T8 (es) 2018-02-26
EP4289446B1 (en) 2025-02-12
EA201071413A1 (ru) 2011-06-30
CA2724194A1 (en) 2009-12-03
EP4289446A2 (en) 2023-12-13
JP2018154656A (ja) 2018-10-04
PT3205334T (pt) 2020-07-31
CY1120351T1 (el) 2019-07-10
EP3714877B1 (en) 2022-01-26
ES2627837T3 (es) 2017-07-31
SI2772249T1 (sl) 2017-08-31
JP2016065095A (ja) 2016-04-28
EP4035656A1 (en) 2022-08-03
AU2009252210A1 (en) 2009-12-03
JP2011521943A (ja) 2011-07-28
HRP20140979T1 (hr) 2014-11-21
TWI432202B (zh) 2014-04-01
PL3714877T3 (pl) 2022-05-16
EP4512424A2 (en) 2025-02-26
SI3714877T1 (sl) 2022-05-31
PL3205334T3 (pl) 2020-11-02
EP3205334B1 (en) 2020-04-29
JP2024079852A (ja) 2024-06-11
KR20110011707A (ko) 2011-02-08
KR101820816B1 (ko) 2018-01-22
MX2010012987A (es) 2011-02-24
BRPI0913109A2 (pt) 2017-06-20
ES3014089T3 (en) 2025-04-16
JP7265584B2 (ja) 2023-04-26
JP2017178957A (ja) 2017-10-05
KR20190067272A (ko) 2019-06-14
GEP20156220B (en) 2015-01-26
PL2306977T3 (pl) 2015-01-30
CY1115565T1 (el) 2017-01-04
EP2306977A1 (en) 2011-04-13
US9999593B2 (en) 2018-06-19
US20210059931A1 (en) 2021-03-04
US20180289618A1 (en) 2018-10-11
JP2021120412A (ja) 2021-08-19
JP6889789B2 (ja) 2021-06-18
AR071937A1 (es) 2010-07-28
ES2907982T3 (es) 2022-04-27
KR20200057801A (ko) 2020-05-26
DK3714877T3 (da) 2022-02-14
JO3039B1 (ar) 2016-09-05
EP4035656B1 (en) 2023-11-22
PT2306977E (pt) 2014-09-22
EP2772249A1 (en) 2014-09-03
KR101650006B1 (ko) 2016-08-22
HUE033103T2 (en) 2017-11-28
US20110152264A1 (en) 2011-06-23
ES2495316T3 (es) 2014-09-17
MY159463A (en) 2017-01-13
DK2772249T3 (en) 2017-07-17

Similar Documents

Publication Publication Date Title
DK2306977T3 (da) Fremgangsmåde og sammensætning til behandling af okulær hypertension og glaukom
DK2326357T3 (da) Sammensætning og fremgangsmåde til behandling af vævsdefekter
DK2796469T3 (da) Hidtil ukendte sammensætninger og fremgangsmåder til behandling af IgE-medierede forstyrrelser
DK2349132T3 (da) Apparat til behandling af gerd
DK2894165T5 (da) Fremgangsmåder og sammensætninger til behandling af komplementforbundne forstyrrelser
DK1911358T3 (da) Ny sammensætning til forbedring af hudkvalitet og fremgangmåde til fremstilling deraf
DK2212070T3 (da) Fremgangsmåde til behandling af træ
DK2207550T3 (da) Tetrahydroquinolinderivater til behandling af post-traumatiske stress-lidelser
DK3284820T3 (da) Fremgangsmåde til behandling af pyropheophytin-holdige sammensætninger
DK2398902T3 (da) Fremgangsmåder og sammensætninger til diagnosticering og behandling af cancer
EP2205372A4 (en) CORRECTION OF A DEVIATION OF THE TUBE LAYER CIRCULAR LAYER WHILE ROUNDING
DK2231678T3 (da) Fremgangsmåde til selektiv deprotonisering og funktionalisering af 1-fluor-2-substituerede 3-chlorbenzener
BRPI0923898A2 (pt) Aparelho e método de distribuição de lentes oftálmicas
DK3216457T3 (da) Forbindelser og fremgangsmåder til forebyggelsen eller behandlingen af restenose
DK2554174T3 (da) Fremgangsmåde til behandling af sygdomme
DK2099446T3 (da) Fremgangsmåde til behandling af inflammatorisk tarmsygdom
DK2501361T3 (da) Fremgangsmåde til behandling af nethindetilstande ved anvendelse af en intraokulær tamponering
DK3199553T3 (da) Fremgangsmåder og midler til diagnosticering og behandling af hepatocellulært carcinom
DK2285416T3 (da) Konjugat til behandlingen af mesotheliom
DK3494960T3 (da) Stabiliserede sammensætninger af alkyleringsmidler og fremgangsmåder til anvendelse af samme
DK2361627T3 (da) Sammensætning til forebyggelse eller behandling af øjensygdomme
DK2340035T3 (da) Behandling af fruktosemalabsorption
BRPI0907329A2 (pt) composição e método de gesso de não hidratação
DK2470214T3 (da) Fremgangsmåde til behandling af svaghed
IL197323A0 (en) Novel method and compositions for prevention or treatment of glaucoma and ocular hypertension